Eli Lilly and Company entered into a definitive agreement to acquire CrossBridge Bio, Inc. for $300 million.

Published: 2026-04-14 13:10:42 ET LLY

Published on 04/14/2026 at 01:10 pm EDT

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire CrossBridge Bio, Inc. for $300 million on April 14, 2026. Under the terms of the agreement, Lilly will acquire CrossBridge Bio, and CrossBridge Bio shareholders could receive up to $300 million in cash, inclusive of an upfront payment and a subsequent payment upon achieving a specified development milestone. Cooley LLP is serving as legal counsel to CrossBridge Bio, and Zwick Advisory, LLC acts as a strategic advisor to the Eli Lilly?s Board of Directors.